Company intelligence
Magnitude Biosciences Ltd
Accelerating R&D with In Vivo C. elegans Data & WormGazer® Technology, De-Risking Clinical Trials and Cutting Costs
About Magnitude Biosciences Ltd
An innovative C. elegans company, using our expertise and technology to provide quantified non-invasive assays of health outcomes for biotech, nutrition and other industries and research interests. - Prescreen compounds to reduce the number of experiments in mammals - Find effective and safe concentration ranges - Test mutants in signalling pathways - Screen libraries of mutants - Screen compound libraries - Combine compounds and mutants - Adapt technology to address your questions We are a team of experts with a proven track record of: Designing customised C. elegans studies to provide answers to your specific ageing research questions Integrating C. elegans into drug discovery pipelines Working with innovative biotech and pharma companies Providing relevant, standardised, data rich assays
Verified activity
Signals from Magnitude Biosciences Ltd
8 published signals
Presence & Recognition
Magnitude Biosciences Ltd is a sponsor of the 75th Annual Scientific Meeting of the British Society for Research on Ageing (BSRA) at Keble College, Oxford, from 9 to 11 September 2026, with Principal Scientist Dr Karthik Mohanraj attending.
Reported by Magnitude Biosciences Ltd
Research & Knowledge
Magnitude Biosciences Ltd used the VivoScan whole-organism phenotypic screening platform to test lifespan-extending effects of Urolithin A in a wide range of concentrations.
Reported by Magnitude Biosciences Ltd
Research & Knowledge
Magnitude Biosciences Ltd tested Urolithin A on WormGazer and found that its beneficial effects extended into overall organismal healthspan, preserving the quality of worms' mobility well into adulthood.
Reported by Magnitude Biosciences Ltd
Research & Knowledge
Magnitude Biosciences Ltd confirmed that Urolithin A increased mean lifespan by up to 24% within 8 weeks of testing.
Reported by Magnitude Biosciences Ltd
Research & Knowledge
Magnitude Biosciences Ltd published the second chapter of its end-to-end Case Study series titled From Molecule to Mechanism, detailing the discovery and characterization of UrolithinA and its effects on healthspan.
Reported by Magnitude Biosciences Ltd
Research & Knowledge
Magnitude Biosciences Ltd tested Compound X on WormGazer and found that its beneficial effects improved overall organismal healthspan beyond lifespan.
Reported by Magnitude Biosciences Ltd
Research & Knowledge
Magnitude Biosciences Ltd performed whole-organism RNAseq on C. elegans treated with Compound X to understand its molecular basis.
Reported by Magnitude Biosciences Ltd
Research & Knowledge
Magnitude Biosciences Ltd concluded its end-to-end Case Study series, screening hundreds of FDA-approved drugs using VivoScan, identifying a standout compound that extended mean lifespan by 65% within 8 weeks.
Reported by Magnitude Biosciences Ltd